High-flow Nasal Oxygen Therapy in Obese Patients Undergoing Sedative Gastroscopy
Launched by XIAOLIANG WANG · Sep 2, 2024
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the use of high-flow nasal oxygen therapy (HFNC) to help obese patients who are undergoing a type of procedure called sedative gastroscopy. Obese patients may have difficulty getting enough oxygen during sedation due to extra soft tissue in their neck and throat. HFNC delivers a high flow of oxygen through a special nasal device, which can help keep the airways open and reduce the risk of low oxygen levels during the procedure. The trial aims to find the best flow rates—30, 50, and 70 liters per minute—to see which one works best for preventing low oxygen levels while keeping patients comfortable.
To participate in this study, patients should be between 18 and 65 years old and undergoing a sedative gastroscopy, among other criteria. Participants will receive oxygen therapy at different flow rates during their procedure. It's important to know that some patients may not be eligible due to specific health conditions or allergies. This research could provide valuable insights into how to make procedures safer for obese patients, ultimately improving their care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients undergoing sedative gastroscopy
- • 2. Aged over 18.
- • 3. ASA classification I-III
- • 4. Interincisal distance \>6.5cm, no micrognathia, limited mouth opening and limited cervical spine movement
- • 5. Compliance with ethics, patient willing to participate in the trial, signed informed consent form
- Exclusion Criteria:
- • 1. Contraindications for endoscopic procedures or patients refusing sedation/anesthesia.
- • 2. Patients with allergies to propofol, eggs, soybeans, or milk.
- • 3. Patients with gastrointestinal obstruction and gastric emptying disorders.
- • 4. Patients with acute pharyngitis, tonsillitis, and upper respiratory tract infections.
- • 5: Patients with acute exacerbations of respiratory diseases such as asthma, bronchitis, and COPD. 6. Patients with acute arrhythmias and severe heart disease (congenital, valvular disease). 7. Patients requiring replacement therapy for severe liver or kidney dysfunction.
- • 8. Patients with severe mental illnesses requiring medication to control symptoms.
- • 9. Patients with moderate to severe anemia, coagulation disorders, and hematological diseases. 10. Patients with severe nasal congestion caused by nasal cavity lesions. 11. Pregnant and lactating patients.
About Xiaoliang Wang
Xiaoliang Wang is a dedicated clinical trial sponsor with a focus on advancing medical research and innovation. With a commitment to improving patient outcomes, Xiaoliang Wang oversees the design, implementation, and management of clinical trials across various therapeutic areas. By fostering collaboration with leading healthcare professionals and leveraging cutting-edge technologies, the organization aims to facilitate the development of new treatments and therapies. Xiaoliang Wang prioritizes ethical conduct and regulatory compliance, ensuring that all trials are conducted with the highest standards of integrity and excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Nanjing, Jiangsu, China
Patients applied
Trial Officials
Xiaoliang Wang
Study Director
The First Affiliated Hospital with Nanjing Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported